New Jersey-based Hackensack Meridian Health has teamed up with the New Jersey Innovation Institute (NJIT) to open a health incubator with a design similar to the reality show ”Shark Tank,” in which companies pitch healthcare innovation ideas to a panel of experts. The incubator, Agile Strategies Lab, is the first of its kind for healthcare advances in New Jersey, according to officials. The lab, located on the New Jersey Institute of Technology (NJIT) campus in Newark, is designed to help create and launch the next wave of problem-solving in healthcare through better devices, improved technology and more efficient services to provide a higher quality of care, lower costs, and an enhanced patient experience, officials said in an announcement.
Hackensack Meridian Health has committed $25 million, a new revenue stream to help companies develop trailblazing products and services. This seed money will help launch ideas to the point where they can become viable and receive financing through venture capitalists. And the organization’s vast network—13 hospitals in seven counties, and more than 100 outpatient centers and 6,000 physicians—will look to serve as a vehicle to test some of the innovations once they are advanced enough as determined by a panel of experts from multiple disciplines.
Penn State professor Ibrahim Ozbolat and his team has engineered a solution to worn out knees. They’re producing cartilage patches to repair defects. Since there are no blood vessels in cartilage tissue, so the researchers said it’s a good type of tissue for bio-printing. In the future, Ozbolat says, stem cells would be removed from a patient and cultured in a lab. The cartilage is printed and then transplanted back into a patient. This will allow scientists to print new and compatible human parts someday.
Dr Jeffrey Lieberman from Columbia University says” the new technologic innovation that is emerging and which does seem likely to impact psychiatry and mental health care in a time that is commensurate with the other specialties of medicine, is the technology that informs how we use Internet-based smartphone mobile app devices. The rudimentary ways in which this has already begun to permeate medicine and mental health care include electronic health records and telemedicine, which is ideally suited to psychiatry in terms of being able to provide consultation at a distance.“The initial idea is to have smartphone-based applications that can perform several functions. One is a monitoring function: having apps that can passively monitor the activities or biologic signals of an individual—whether it is movement, heart rate, respiratory rate, or level of activity—and have an ongoing record that can be catalogued, observed, and interpreted by clinicians. A second function is as a means of communication. Doctors already have begun to employ FaceTime, Skype, and texting to maintain contact with patients remotely in a variety of situations. Another area would be to develop apps that could provide some kind of actual therapeutic assistance, including cognitive-behavioral therapy, motivational interviewing, and supportive types of techniques or protocols when needed. All of these have great potential and can expand the reach of healthcare providers, psychiatrists, and mental health care clinicians, and provide help to a larger proportion of people when they need it.”
23andMe first debuted direct-to-consumer tests meant to predict disease in 2013, but the U.S. Food and Drug Administration quickly clamped down on that and told the company to stop marketing the tests, saying they could be inaccurate and confusing to consumers.
However, the company was vindicated earlier this year when the FDA revised that decision, declaring 23andMe could sell tests that estimate customers’ risk of certain disease, as long as they don’t purport to diagnose any disease.
Early this year, Illumina, the manufacturer of most of the world’s DNA sequencers, unveiled its newest, most efficient machine, NovaSeq, which can sequence as many as 48 entire human genomes in two and a half days, according to the company. Illumina claims the ultra-fast machine will usher in the $100 genome and will open the door for researchers to cheaply sequence DNA in search of rare genetic variants that cause disease.
Sophia Genetics is taking a big-data approach to DNA. The Swiss company is using AI algorithms to continuously learn from thousands of patients’ genomic data. Partnering hospitals take patient samples and run them through a DNA sequencer. The Sophia system sifts through that genetic information to identify mutations in a patient’s genome. The technology is said to quickly and more accurately diagnose conditions like cancer, metabolic disorders, and heart disease.
Sir Venki Ramakrishnan says risks and benefits of germline therapy, which is banned in Britain, should be debated
An international team of scientists, led by researchers at the Oregon Health and Science University, has used genetic engineering on human sperm and a pre-embryo. The group says is doing basic research to figure out if new forms of genetic engineering might be able to prevent or repair terrible hereditary diseases. Congress has banned federal funding for genetic engineering of sperm, eggs, pre-embryos or embryos. That means everything goes on in the private or philanthropic world here or overseas, without much guidance. It should be determined who should own the techniques for genetic engineering. Important patent fights are underway among the technology’s inventors. Which means lots of money. is at stake. And that means it is time to talk about who gets to own what and charge what. Finally, human genetic engineering needs to be monitored closely: all experiments registered, all data reported on a public database and all outcomes — good and bad — made available to all scientists and anyone else tracking this area of research. Secrecy is the worst enemy that human genetic engineering could possibly have. Today we need to focus on who will own genetic engineering technology, how we can oversee what is being done with it and how safe it needs to be before it is used to try to prevent or fix a disease. Plenty to worry about.
Hospitals around the world are constantly for new and innovative ways to battle deadly pathogens and kill multidrug resistant organisms that can cause hospital-acquired infections (HAI).
Saint Peter’s University Hospital has implemented a LightStrike Germ-Zapping Robot that emits waves of ultraviolet (UV) light to destroy hard-to-kill bugs in hard-to-clean places.
Their goal is to prevent infection & provide a clean, safe environment for their patients, families and employees. The latest technology provides an added level of protection in combating HAI’s caused by pathogens such as Clostridium difficile and Staphylococcus aureus.
The Xenex robot is a new technology that uses pulsed xenon, a high-intensity UV light that penetrates the cell walls of microorganisms, including bacteria, viruses, mold, fungus and spores. Their DNA is fused, rendering them unable to reproduce or mutate, effectively killing them on surfaces without contact or chemicals.
The system is effective against even the most dangerous pathogens, including Clostridium difficile (C. diff), norovirus, influenza, Ebola and methicillin-resistant Staphylococcus aureus, better known as MRSA. Over 400 hospitals, Veterans Affairs and Department of Defense facilities in the U.S., Canada, Africa, Japan and Europe are using Xenex robots, which are also in use in skilled nursing facilities, ambulatory surgery centers, and long-term acute-care facilities.
Scientist say, Genome engineering technology offers unparalleled potential for modifying human and nonhuman genomes. In humans, it holds the promise of curing genetic disease, while in other organisms it provides methods to reshape the biosphere for the benefit of the environment and human societies. However, theses opportunities come unknown risks to human health and well-being.
An illustration of the CRISPR-Cas9 gene editing complex from Streptococcus pyogenes. The Cas9 nuclease protein uses a guide RNA sequence to cut DNA at a complementary site.Science Photo Library/Getty Images
Indian origin Kashmiri doctor along with other scientists has developed genetically modified human embryos in the US. Led by prestigious Stanford University in the U.S., they raise public concerns that editing an embryo to fix a genetic disease, as was done this week, could be seen as “playing God” in an effort to create only the “best children” possible. This is also seen as a first step towards having “designer babies http:///2017/08/06/in-short-gene-editing-explained-in-thirty-seconds/
Scientist say CRISPR is good for eradicating disease.